Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07412288 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
A Phase 1 study of Healthy Participants, sponsored by Kymera Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT07412288 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Kymera Therapeutics. The registered enrollment target is 96 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07412288, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Kymera Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG KT-579
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07412288
The ClinicalTrials.gov registry entry for NCT07412288 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (48% higher). The listed sponsor is Kymera Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07412288 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT07412288 about?
NCT07412288 is a clinical study titled "First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants". This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.
What is the current status of trial NCT07412288?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2026-02-23. Estimated completion is 2026-12.
What conditions does trial NCT07412288 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07412288?
The interventions under investigation include: Placebo (DRUG), KT-579 (DRUG).
Who is sponsoring clinical trial NCT07412288?
This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07412288 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.